TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and Posttraumatic Stress Disorder in Physical Trauma Victims in the Medical Setting
Brief Summary: The purpose of this study is to examine the efficacy of escitalopram compared to placebo in reducing Acute Stress Disorder (ASD) symptoms and in preventing the emergence of Post-Traumatic Stress Disorder (PTSD) in patients with medical trauma who are at risk for the development of PTSD based on the presence of ASD symptoms.


Options:
A: Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): saline | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
B: Arm Label: Hydrocortisone injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline 0.9% | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone injection | Intervention Type: DRUG; Name: normal saline 0.9%; Assigned to Arm(s): normal saline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Control Evaluation (ACE): A Biomarker-Based Approach to Improving Asthma Control and Mechanistic Studies (DAIT ICAC-02)
Brief Summary: The purpose of ICAC-01 is to determine whether an asthma treatment strategy that measures exhaled nitric oxide (eNO) to indicate disease progression is more effective in treating asthma symptoms when combined with existing asthma treatment guidelines than treatment using the guidelines alone.


Options:
A: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
B: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
C: Arm Label: FeNO group; Type: N/A; Interventions: Device: measurement of exhaled NO is used to guide treatment | Arm Label: Symptom group; Type: N/A; Interventions: N/A | Intervention Type: DEVICE; Name: measurement of exhaled NO is used to guide treatment; Assigned to Arm(s): FeNO group
D: Arm Label: High dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Arm Label: Low dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Low dose ICS | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): High dose ICS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Control Evaluation (ACE): A Biomarker-Based Approach to Improving Asthma Control and Mechanistic Studies (DAIT ICAC-02)
Brief Summary: The purpose of ICAC-01 is to determine whether an asthma treatment strategy that measures exhaled nitric oxide (eNO) to indicate disease progression is more effective in treating asthma symptoms when combined with existing asthma treatment guidelines than treatment using the guidelines alone.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
D: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Control Evaluation (ACE): A Biomarker-Based Approach to Improving Asthma Control and Mechanistic Studies (DAIT ICAC-02)
Brief Summary: The purpose of ICAC-01 is to determine whether an asthma treatment strategy that measures exhaled nitric oxide (eNO) to indicate disease progression is more effective in treating asthma symptoms when combined with existing asthma treatment guidelines than treatment using the guidelines alone.


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Biological: Omalizumab, Biological: Placebo fluticasone | Arm Label: Inhaled Corticosteroid Boost Therapy (ICS); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Corticosteroid Boost Therapy (ICS), Biological: Placebo omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo omalizumab, Biological: Placebo fluticasone | Intervention Type: BIOLOGICAL; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Inhaled Corticosteroid Boost Therapy (ICS); Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS) | Intervention Type: BIOLOGICAL; Name: Placebo omalizumab; Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS), Placebo | Intervention Type: BIOLOGICAL; Name: Placebo fluticasone; Assigned to Arm(s): Omalizumab, Placebo
B: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
C: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
D: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction
Brief Summary: The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1
B: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Auto-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Auto-hMSCs | Arm Label: Allo-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Allo-hMSCs | Intervention Type: BIOLOGICAL; Name: Auto-hMSCs; Assigned to Arm(s): Auto-hMSCs | Intervention Type: BIOLOGICAL; Name: Allo-hMSCs; Assigned to Arm(s): Allo-hMSCs
D: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Vehicle Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Vehicle Control | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Vehicle Control; Assigned to Arm(s): Vehicle Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction
Brief Summary: The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).


Options:
A: Arm Label: Mesenchymal stem cell treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesenchymal stem cell | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Control group | Intervention Type: DRUG; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment group | Intervention Type: DRUG; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Arm Label: Late; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Intervention Type: PROCEDURE; Name: intracoronary bone marrow cells infusion; Assigned to Arm(s): Early, Late
C: Arm Label: The treatment group; Type: EXPERIMENTAL; Interventions: Procedure: Intracoronary injection of autologous bone marrow mononuclear cells | Arm Label: the control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intracoronary injection of autologous bone marrow mononuclear cells; Assigned to Arm(s): The treatment group
D: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis
Brief Summary: The purpose of this study is to see which of the two most common drugs used to treat bronchiolitis works better. A child's participation in this study is expected to last less than 4 hours. Approximately 600 patients will be recruited to participate in this study at Kern Medical Center (KMC).

Bronchiolitis is a very common lung infection in babies. There are many drugs used to treat this disease but nobody knows which one, if any, works the best. Two of the most commonly used drugs are albuterol and epinephrine. These are both drugs given during breathing treatments with oxygen and a mask. We are doing this study to see which of these drugs works better or if they are both equally good. The study works as follows: after the consent process the baby gets three treatments.

* Nebulizer 1 (Treatment)
* Treatment + 30 minutes (approximately) Nebulizer 2
* Treatment + 60 minutes (approximately) Nebulizer 3
* Treatment + 120 minutes (approximately)

The baby will be reevaluated and either discharged home or revert to standard therapy. If the baby is discharged directly from the emergency department (E.D.), we will call you in three days time to see how he/she is doing.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
B: Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albuterol (salbutamol); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: nebulized epinephrine and nebulized albuterol; Assigned to Arm(s): N/A
D: Arm Label: heliox; Type: OTHER; Interventions: Drug: heliox | Arm Label: oxygen; Type: OTHER; Interventions: Drug: oxygen | Intervention Type: DRUG; Name: heliox; Assigned to Arm(s): heliox | Intervention Type: DRUG; Name: oxygen; Assigned to Arm(s): oxygen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biologic Response of Menopausal Women to 17B-Estradiol
Brief Summary: The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: 17B-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17B-estradiol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: 17B-estradiol; Assigned to Arm(s): 17B-estradiol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Brief Summary: SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly cyclophosphamide (Cytoxan) in the treatment of scleroderma.


Options:
A: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: mHSCT; Type: EXPERIMENTAL; Interventions: Biological: mHSCT | Arm Label: cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide | Intervention Type: BIOLOGICAL; Name: mHSCT; Assigned to Arm(s): mHSCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
C: Arm Label: stem cell trasplantation; Type: EXPERIMENTAL; Interventions: Procedure: stem cell transplantation | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care | Intervention Type: PROCEDURE; Name: stem cell transplantation; Assigned to Arm(s): stem cell trasplantation
D: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes
Brief Summary: Optimizing the social and physical ambiance during mealtimes in Dutch nursing homes: implementation and evaluation of the effect with respect to quality of life, nutritional status and physical performance.


Options:
A: Arm Label: usual mealtime care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mealtime assistance; Type: EXPERIMENTAL; Interventions: Other: trained volunteer mealtime assistance | Intervention Type: OTHER; Name: trained volunteer mealtime assistance; Assigned to Arm(s): mealtime assistance
B: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as usual | Arm Label: Received nutrition supplement as needed; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutritional supplement, Other: Treatment as usual | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional supplement; Assigned to Arm(s): Received nutrition supplement as needed | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Control, Received nutrition supplement as needed
D: Intervention Type: PROCEDURE; Name: family style dinner; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer
Brief Summary: This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF (cyclophosphamide, epirubicin and 5-fluorouracil) or to receive 3 cycles of docetaxel plus capecitabine followed by 3 cycles of CEX (cyclophosphamide, epirubicin and capecitabine). The study participants are required to to have a medium to high risk for breast cancer recurrence. The primary aim of the study is to investigate whether addition of capecitabine to a standard taxane/anthracycline regimen will influence recurrence-free survival.


Options:
A: Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A
C: Arm Label: A (experimental group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Capecitabine, Drug: Trastuzumab | Arm Label: B (control group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A (experimental group) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): A (experimental group), B (control group)
D: Arm Label: Arm A: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: Epirubicin, Drug: Cyclophosphamide | Arm Label: Arm B: ET-X; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Capecitabine, Drug: Epirubicin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm B: ET-X | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: EC-T

Answer: B